- Home
- HHS vs APVO Comparison
HHS vs APVO Comparison
Compare HHS & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- APVO
- Stock Information
- Founded
- HHS 1923
- APVO 2016
- Country
- HHS United States
- APVO United States
- Employees
- HHS N/A
- APVO N/A
- Industry
- HHS Advertising
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- HHS Consumer Discretionary
- APVO Health Care
- Exchange
- HHS Nasdaq
- APVO Nasdaq
- Market Cap
- HHS 26.9M
- APVO 21.7M
- IPO Year
- HHS N/A
- APVO N/A
- Fundamental
- Price
- HHS $3.34
- APVO $1.42
- Analyst Decision
- HHS
- APVO
- Analyst Count
- HHS 0
- APVO 0
- Target Price
- HHS N/A
- APVO N/A
- AVG Volume (30 Days)
- HHS 290.4K
- APVO 4.4M
- Earning Date
- HHS 11-13-2025
- APVO 11-10-2025
- Dividend Yield
- HHS N/A
- APVO N/A
- EPS Growth
- HHS N/A
- APVO N/A
- EPS
- HHS N/A
- APVO N/A
- Revenue
- HHS $174,951,000.00
- APVO N/A
- Revenue This Year
- HHS $6.54
- APVO N/A
- Revenue Next Year
- HHS N/A
- APVO N/A
- P/E Ratio
- HHS N/A
- APVO N/A
- Revenue Growth
- HHS N/A
- APVO N/A
- 52 Week Low
- HHS $3.06
- APVO $1.32
- 52 Week High
- HHS $7.45
- APVO $298.00
- Technical
- Relative Strength Index (RSI)
- HHS 42.94
- APVO 40.34
- Support Level
- HHS $3.26
- APVO $1.48
- Resistance Level
- HHS $3.65
- APVO $1.57
- Average True Range (ATR)
- HHS 0.18
- APVO 0.09
- MACD
- HHS -0.02
- APVO -0.00
- Stochastic Oscillator
- HHS 10.09
- APVO 3.13
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.